Buspirone and diazepam in anxiety: a controlled study.
The anxiolytic properties of buspirone were assessed in a 4-week double-blind study in 240 anxious patients, 81 of whom received buspirone, 81 diazepam, and 78 placebo. Patients were required to have scores greater than or equal to 9 on the Covi and greater than or equal to 18 on the Hamilton Rating Scale for Anxiety, and to endorse at least 5 items on a 17-item Anxiety Entry Checklist. Among 212 evaluable patients, those who improved most were married, well-educated females who had both a positive family adjustment and a low level of depression. Diazepam produced relatively equal improvement in females and males. Diazepam seems more effective in reducing somatic symptoms, while buspirone appears more effective in reducing symptoms associated with cognitive and interpersonal problems. Main differences between the drugs were seen in side effect profiles.
D000328:Adult; D000553:Ambulatory Care; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D002065:Buspirone; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008393:Marriage; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012737:Sex Factors
D014151:Anti-Anxiety Agents; D011743:Pyrimidines; D003975:Diazepam; D002065:Buspirone